Introduction
Chronic myeloid leukemia (CML) has undergone a remarkable transformation from a fatal malignancy to a chronic condition compatible with near-normal life expectancy. This evolution, spanning 2001–2026, has been driven by the sequential development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) with increasing potency, selectivity, and novel mechanisms of action1617. Current treatment paradigms emphasize deep molecular response (DMR) achievement, risk-adapted therapy selection, and treatment-free remission (TFR) as the ultimate goal214. However, resistance mechanisms—particularly kinase domain mutations such as T315I and compound mutations—continue to challenge a subset of patients516. This review synthesizes the generational progression of CML therapy, addresses mutation-directed resistance management, and outlines emerging strategies toward functional cure.
Evolution of TKI Generations: Mechanisms and Clinical Evidence
First-Generation: Imatinib and the Foundation of Targeted Therapy
Imatinib mesylate, approved in 2001, established BCR-ABL inhibition as the cornerstone of CML management by competitively binding the ATP-binding site of the BCR-ABL1 kinase17. While revolutionary in converting CML from a rapidly fatal disease to a manageable chronic condition, imatinib's limitations became apparent: incomplete molecular response in many patients and emergence of resistance mutations, particularly in patients with high-risk disease18.
Second-Generation TKIs: Overcoming Imatinib Resistance
Dasatinib (a dual BCR-ABL/Src-family kinase inhibitor) and nilotinib (an imatinib analogue with enhanced potency) emerged in 2006–2007, demonstrating significant activity in imatinib-resistant or -intolerant patients9. These agents showed superior rates of deep molecular response in frontline settings, with ENESTnd demonstrating cumulative TFR eligibility of 47.3–48.6% in nilotinib arms versus 29.7% with imatinib at 10 years2. However, both second-generation TKIs are ineffective against the T315I gatekeeper mutation, a critical limitation affecting approximately 16–24% of resistant patients59. Bosutinib represents another second-generation option with a distinct safety profile16.
Third-Generation: Ponatinib and the T315I Solution
Ponatinib (approved 2012) was specifically designed to overcome T315I through its unique triple-bond scaffold, representing the first ATP-competitive TKI active against this mutation16. However, arterial-occlusive events limited its use, necessitating dose optimization strategies and careful cardiovascular risk assessment.
Fourth-Generation: Asciminib and Allosteric Inhibition
Asciminib (approved 2021) represents a paradigm shift as the first Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor1. By binding the ABL myristoyl pocket rather than competing for the ATP-binding site, asciminib enables rational combination with ATP-competitive TKIs without pharmacokinetic antagonism1.
Key Clinical Evidence for Asciminib:
| Trial | Population | Comparator | Primary Endpoint | Key Findings |
|---|---|---|---|---|
| ASC4MORE1 | DMR-refractory on imatinib ≥1 year | Imatinib/nilotinib | MR4.5 at week 48 | 28.6% (asciminib 60mg + imatinib) vs 0% (imatinib) vs 4.8% (nilotinib) |
| ASCEMBL34 | Failed ≥2 prior TKIs | Bosutinib 500mg QD | MMR at week 24 | 37.6% vs 15.8% (p=0.001); superior at week 156: 33.8% vs 10.5% |
At week 156 follow-up of ASCEMBL (median 3.7 years), asciminib maintained superior major molecular response (MMR) rates with cumulative incidence of 45.2% versus 23.7% for bosutinib4. Critically, among 25 patients who switched from bosutinib to asciminib after lack of efficacy, only modest responses were achieved (8% MMR), suggesting earlier incorporation of asciminib may improve outcomes4.
Emerging Agents: Olverembatinib
Olverembatinib represents an emerging option for heavily pretreated populations with resistance or intolerance to ponatinib and/or asciminib, reflecting recognition that additional agents are needed for complex resistance patterns812.
Resistance Biology and Mutation Landscape
Mechanisms of Resistance
Resistance to TKIs is multifactorial, encompassing17:
- BCR-ABL1 kinase domain mutations (most common)
- BCR-ABL1 gene amplification
- Activation of BCR-ABL-independent pathways
- Altered drug transport/metabolism
- Non-adherence
- Leukemic stem cell persistence
T315I: The Gatekeeper Mutation
T315I emerged as a clinically pivotal resistance mutation across TKI generations, detected in 16% of imatinib-resistant patients and 24% of dasatinib/nilotinib-treated patients5. This mutation abolishes a critical hydrogen bond required for binding of imatinib, dasatinib, nilotinib, and bosutinib16. Dynamic mutation analysis revealed that among 32 imatinib-resistant patients with baseline mutations, all nine patients who developed new mutations during second-generation TKI therapy acquired T315I5. Currently, only ponatinib, asciminib, and olverembatinib retain activity against T315I16.
Compound Mutations and Evolutionary Trajectories
Preclinical studies of novel inhibitors targeting T315I identified emergence of compound mutations involving both P-loop and T315I positions, highlighting that even potent gatekeeper-targeting agents face evolutionary resistance7. Patients with baseline imatinib-resistant mutations had significantly higher mutation development rates during second-generation TKI therapy (28%) compared with patients without baseline mutations (17%), indicating prior mutation burden predicts subsequent resistance evolution5.
Current Treatment Algorithms and Monitoring Standards
Frontline Selection and Risk Stratification
Four TKIs are FDA-approved for first-line treatment of newly diagnosed CML in chronic phase (CML-CP): imatinib, dasatinib, bosutinib, and nilotinib16. No clear overall survival advantage has been demonstrated among approved frontline TKIs in randomized trials, although second-generation TKIs achieve faster and deeper molecular responses16.
The European LeukemiaNet (ELN) 2020 guidelines recommend the EUTOS Long-Term Survival (ELTS) score over the Sokal score for prognostic stratification, as age has less negative prognostic impact in the TKI era2. High-risk additional chromosomal abnormalities (including +8, second Philadelphia chromosome, i(17q), +19, −7/7q−, 11q23, or 3q26.2 aberrations) predict poorer TKI response and warrant classification as high-risk disease2.
Molecular Response Definitions and Milestones
Molecular response is reported on the International Scale (IS) as BCR::ABL1 ratio to ABL1 transcripts2:
- MMR/MR3: BCR::ABL1 ≤0.1% (major molecular response)
- MR4: BCR::ABL1 ≤0.01% (deep molecular response)
- MR4.5: BCR::ABL1 ≤0.0032% (very deep molecular response)
BCR::ABL1 ≤1% IS is equivalent to complete cytogenetic remission. Treatment failure is defined by BCR-ABL1 >10% at 3 months when confirmed2. The DASCERN trial demonstrated that patients failing to achieve early molecular response at 3 months who switched to dasatinib achieved significantly higher 5-year cumulative MMR rates (77% vs 44%, p<0.001) with median time to MMR of 13.9 versus 19.7 months18, validating early intervention strategies.
Treatment-Free Remission Criteria
To attempt TFR, patients must achieve sustained DMR defined as MR4.5 for ≥2 years or MR4 for ≥3 years prior to discontinuation2. TFR eligibility remains limited: by 5 years, 35–67% of newly diagnosed patients do not achieve DMR across major trials2. However, TFR has emerged as the major goal in selected patients, particularly in younger patients, representing a functional cure state1416.
Strategies for T315I and Compound Mutations
Mutation-Directed TKI Selection
Patients developing T315I display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib16. Choice depends on patient and disease characteristics: comorbidities (particularly cardiovascular risk factors), financial considerations, disease stage, and complete mutational profile16.
Combination and Allosteric Strategies
The ASC4MORE trial pioneered combination therapy using asciminib's unique allosteric mechanism. Adding asciminib 60 mg once daily to imatinib in 84 patients who failed to achieve DMR after ≥1 year of imatinib monotherapy resulted in 28.6% achieving MR4.5 at week 48 versus 0% on continued imatinib1. By week 96, cumulative MR4.5 rates remained superior (28.6% vs 9.5%). Notably, 14 patients crossing over from imatinib to asciminib 60 mg after failing to achieve MR4.5 showed 28.6% cumulative MR4.5 achievement, demonstrating salvage potential1.
No arterial-occlusive events occurred in asciminib add-on arms, whereas one carotid stenosis occurred with nilotinib, supporting asciminib's favorable cardiovascular safety profile1. This combination strategy aims to suppress resistant BCR::ABL1 mutant outgrowth through dual mechanism targeting1.
Preclinical studies demonstrated that BCR-ABL siRNA combined with nilotinib increased inhibition of proliferation and apoptosis in T315I cells (p<0.0001) and reversed multidrug resistance-1 gene-dependent resistance (p<0.01)13, suggesting gene silencing approaches may complement TKIs for resistant mutations.
Role of Allogeneic Stem Cell Transplantation
Allogeneic stem cell transplantation remains critical for patients with CML-CP and failure (due to resistance) of at least two TKIs and for all patients in advanced-phase disease16. Case reports document successful pretreatment with dasatinib (16–19 days) followed by transplantation in blast crisis patients harboring F359V mutations, demonstrating rapid cytoreduction strategies before transplantation11.
Future Directions: Toward Functional and Operational Cure
Redefining Disease Classification and Risk
Recent analysis of 2,122 consecutive CML patients challenged traditional accelerated phase classification, demonstrating that patients with increased basophils only had similar outcomes to chronic phase intermediate-risk patients, supporting the 2022 WHO classification eliminating accelerated phase as a distinct category6. This refinement enables more precise risk stratification and treatment allocation.
Novel Mechanisms Beyond ATP-Site Inhibition
Type-II kinase inhibitors such as GNF-7 demonstrated potent inhibition of wild-type and T315I BCR-ABL as well as clinically relevant mutants (G250E, Q252H, Y253H, E255K, E255V, F317L, M351T) through alternative binding modes affecting P-loop flexibility and disrupting the hydrophobic spine19. AP24163 similarly demonstrated activity against T315I through structural strategies distinct from ATP-competitive inhibitors, establishing conceptual foundations for allosteric inhibitor development7.
Unmet Needs and Ongoing Questions
A 2025 perspective questioned whether another TKI is needed for CML, reflecting debate about optimal sequencing and combination strategies10. However, substantial populations remain with suboptimal responses, resistance mutations, or intolerance, justifying continued development of agents with novel mechanisms10.
Key controversies include which TKI is optimal for initial therapy and what depth/duration of molecular remission is needed for TFR14. Emerging modalities under investigation include next-generation BCR-ABL1 inhibitors active against compound mutations, PROTAC-like degraders, and potential immunotherapeutic approaches targeting leukemic stem cells and minimal residual disease1416.
Conclusion
The evolution of CML therapy from 2001–2026 demonstrates transformation from a fatal disease to one where functional cure through TFR is achievable in an increasing proportion of patients. The sequential development of TKI generations—from imatinib through second-generation agents to ponatinib and the allosteric inhibitor asciminib—has systematically addressed resistance mechanisms while improving safety profiles. Current evidence supports early molecular monitoring, mutation-guided TKI selection, and rational combination strategies to maximize DMR achievement. The T315I gatekeeper mutation, once universally fatal, now has multiple therapeutic options including ponatinib, asciminib, and emerging agents. Future strategies combining allosteric inhibition, novel binding modes, and potential stem cell-targeting approaches promise to expand the population achieving operational cure, with TFR representing the major goal in selected patients in this remarkable success story of targeted cancer therapy.